Announcement PDF ASX Announcement 20 March 2025 Webinar Presentation: Diagnostics Deep Dive Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a company at the forefront of microbiome diagnostics & therapeutics, is pleased to release the presentations for the Webinar, ‘Diagnostics Deep Dive’ to be held at 11am AEDT / 10am AEST today, Thursday 20 March 2025 via Zoom (details below) The Presentation is provided in two parts: - Part A: Diagnostics Opportunity, Products and Growth Strategy (Attached to this announcement) - Part B: Diagnostics Growth & Metrics (Released separately) Registration: Investors and interested parties can pre-register for the webinar via the following link: https://us02web.zoom.us/webinar/register/WN_cCE7UNnHQbu8KQsz2WgwLA A recording will be made available on the company’s website following the webinar. Further webinars will be scheduled in the coming months, covering other important aspects of Microba’s business This announcement has been authorised for release by the Board of Directors. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 At the forefront of microbiome diagnostics & therapeutics Diagnostics Deep Dive ASX: MAP 20 MARCH 2025 Authorised for release by the Board of Directors Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above. Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended. Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance. Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright. Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation. 2 Presenters Luke Reid Chief Executive Officer 3 Eric Davis Chief Growth Officer Chris Saad Chief Product Officer Lutz Krause Chief Scientific Officer Today’s deep dive agenda Topic Presenter Executive Summary Dr. Luke Reid, CEO The Microbiome Opportunity Dr. Luke Reid, CEO Why Microba? Dr. Luke Reid, CEO Our Diagnostics Strategy Problem Solution Market Product Deep Dive Growth Deep Dive Evidence Deep Dive Dr. Luke Reid, CEO Mr Chris Saad, CPO Mr Eric Davis, CGO Assoc. Prof. Lutz Krause, CSO Our Traction Dr. Luke Reid, CEO Doubling down on the $25B opportunity Dr. Luke Reid, CEO Summary Dr. Luke Reid, CEO Q&A Mr John Polinelli, Head of IR to moderate 4 Key Take Home Messages 5 • The market for this new diagnostic category of microbiome testing is potentially worth more than $100B • Our focus today is patients with unresolved GI disease, a $25B market opportunity • 2 world leading products addressing these patients – MetaPanel & MetaXplore • A world class product engine – continuously improving products and shipping value one facet at a time • Scalable growth engine with multiple channels and tactics, and a staged approach to customers & regions • Partnerships with two of the world’s largest medical diagnostic co’s - Sonic Healthcare & SYNLAB • All driving to a north star metric of 1 million tests • Accelerating traction in our first two markets – Australia & United Kingdom, USA to follow • Doubling down by focusing on the products designed for scale – replacing old product lines​ PART A: Diagnostics Opportunity, Products & Growth Strategy SECTION 1 The Microbiome Opportunity The next frontier in precision healthcare 6 7 Chronic diseases remain difficult to diagnose, treat, manage and cure Gastrointestinal Mental Cardiovascular Cancer Autoimmune Allergy 8 Chronic diseases collectively represent over 90% of healthcare spend in the US. US$4 Trillion Ninety percent of the nation’s US$4.5 trillion in annual health care expenditures are for people with chronic and mental health conditions* Gastrointestinal Mental Cardiovascular https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html Cancer Autoimmune Allergy 9 The gut microbiome is implicated in all of these conditions. 21,000+ Research publications demonstrate a clear link between chronic diseases and the gut microbiome* Gastrointestinal Mental Cardiovascular Cancer Autoimmune PubMed search terms "gut microbiome/microbiota" or "stool microbiome/microbiota" or "faecal microbiome/microbiota" and "disease" Allergy 10 Changing the gut microbiome can treat chronic disease. 150+ Global clinical studies demonstrate that microbiome modulation can influence disease outcomes and clinical symptoms* Gastrointestinal Mental Cardiovascular Cancer Autoimmune Allergy PubMed search terms "gut microbiome" and "modulate" and "clinical study" and manually selecting for clinical trials with positive results indicated in the abstracts. Combating chronic disease through microbiome diagnostics and therapeutics $1.4 trillion healthcare disruption opportunity Microbiome testing to diagnose and match patients with the right treatment Microbiome therapy to treat chronic diseases $125B Est. TAM $1.3T Est. TAM Management estimate based on desktop study of the total number of patients across the top 10 chronic diseases impacted by the microbiome, across the United States, United Kingdom, Australia, France, Germany, Spain & Italy. Conservative diagnostic and therapeutic pricing in USD applied based on existing predicates. 11 12 “Our partnership with Microba exemplifies our commitment to invest in cutting edge developments in laboratory medicine. We see microbiome testing becoming a key part of pathology over coming years and are excited about the potential of this partnership and the opportunities that Microba's technology will provide for Sonic’s global operations, our referring clinicians and our patients.” Dr Colin Goldschmidt – CEO, Sonic Healthcare 13 SECTION 2 Why Microba? The world's leading clinical Microbiome company Microba is the world’s leading clinical Microbiome company - proven science & real patient outcomes Deep bench of world-class leaders Clear, global & ambitious vision Family of mutuallyreinforcing businesses Proprietary technology powered flywheels 14 Impact and growthoriented cultural values Founded and operated by deep bench of world-class leaders Prof. Gene Tyson Co-Founder Dr Luke Reid Chief Executive Officer Prof. Phil Hugenholtz Co-Founder Mr James Heath Chief Financial Officer Mr Chris Saad Chief Product Officer Prof Trent Munro SVP Therapeutics Dr Nicola Angel Laboratory Director Dr David Wood Chief Technology Officer 15 Eric Davis Chief Growth Officer Mr Drew Webb Assoc. Prof. Lutz Krause Mr Simon Mangan Mr Alaster Stockwell-Jones Chief Marketing Officer Chief Scientific Officer UK Managing Director UK Commercial Director Clear, global and ambitious vision Broad-based acceptance Regular testing is commonplace The microbiome is recognised by healthcare professionals and patients as critical to health and disease management. High quality and clinically useful microbiome testing is performed regularly – initiated both by patients and clinicians. Usage of approved therapeutics is routine Microbiome therapeutics are approved and in routine use for both maintenance and the treatment of multiple chronic diseases. 16 Millions of patients living healthier lives Microbiome diagnostics and therapeutics have materially improved millions of patient lives – driving yet further awareness and adoption. Family of mutually-reinforcing businesses 17 Diagnostics Supplements Therapeutics Clinical microbiome diagnostics Efficacious microbiome supplements Precision microbiome therapeutics Multiple tests. Clinically formulated, evidence-based portfolio Data driven therapeutic development platform. GASTROINTESTINAL PATHOGEN TEST We work with world leading diagnostic companies to educate the market, drive awareness and support access to our diagnostic tests. DIRECT TO PRACTITIONER CHANNEL We have world-class clinical marketing, education, and sales teams who drive adoption of our diagnostic tests. Registered clinical diagnostic products. Clinician referral required. ADVANCED AI/ML APPROACH UNDERPINNED BY WORLD LEADING TECHNOLOGY DISTRIBUTOR CHANNEL We work with distributors who supply clinicians and patients with access to clinical formulated products provided under referral. DIRECT TO PRACTITIONER CHANNEL We have world-class marketing, education, and sales teams who drive adoption of our clinically formulated products. NOVEL PIPELINE – POTENT, ORAL DELIVERY, SAFE & MANUFACTURABLE 3 programs. 2 channels to market. 2 channels to market. PARTNER CHANNEL DISTRUTED FORMULATIONS IN-HOUSE FORMULATIONS GASTROINTESTINAL DISORDERS TEST INFLAMMATORY BOWEL DISEASE PROGRAM IMMUNOONCOLOGY PROGRAM AUTOIMMUNE DISEASE PROGRAM CLINICAL INDICATION Mild-moderate Ulcerative Colitis CLINICAL INDICATION Multiple cancers to enhance checkpoint inhibitor response CLINICAL INDICATION Lupus, psoriatic arthritis & autoimmune liver disease Healthcare professional only products. Clinician referral required. World leading microbiome analysis technology | Proprietary databank | Advanced AI and biostatistics Discovery. Early clinical de-risking. Out licensing to pharma. Microba’s tests leverage the world's largest, clinically applicable, proprietary microbiome dataset • Broad-based species coverage Built from public genomes, proprietary genomes, and MAGs from 90,000+ global metagenomic samples. • Precise organisation powered by GTDB taxonomy The de facto standard, developed by Microba cofounder Prof. Phil Hugenholtz. • Global patient coverage Combines accurate microbiome data with patient health data from 60,000+ patients worldwide. • Designed for healthcare applications Precise mappings between species data and patient data to power clinically relevant insights and recommendations. *Numbers as @ Jun 2024 >100TB of DNA data >90,000 metagenomes covering various geographic locations >1,000 >1M health indicators/participants >100M genes genomes >100k species 18 Competitive Moat 1 – Science & Data Flywheel 6. More Data Collection More anonymous, proprietary patient data 1. The Most Proprietary Data World's largest, clinically applicable, proprietary microbiome dataset 5. More Engagement More patients and patient health tracking 2. More Clinical Utility Leading diagnostic performance, interpretations & suggested actions 4. More frequent referrals More clinical referrals 3. Better Outcomes Improved patient health outcomes 19 Competitive Moat 2 – Product Led Network Effects 5. Increased retention Increased retention, retesting, and clarity for all stakeholders 1. More Features World-leading patient interpretability and collaboration features 4. Improved Health Outcomes Improved patient health outcomes 2. More Sharing More patient sharing with families, friends, and broader clinical care teams 3. Richer Care Graph Growing graph of relationships, tests/test data, patients, families, and clinicians 20 21 SECTION 3 Microba's Diagnostics Strategy A vision for improved patient health outcomes at scale Solving real patient problems at the intersection of bits, biology and atoms. 22 Software Science Ops GTM Patient Experiences Metagenomics Testing Kit Operations Brand Clinician Experiences Bioinformatics Operational Tools + Molecular assays Clinical Evidence ... + Lab Operations Customer Support ... + Direct Sales Product Led Growth Referral Partners Artificial Intelligence Customer Service Agents Foundational Biology Models Data-Driven Decision Making Predictive Analytics 23 SUB-SECTION 3.1 The Diagnostic Problem 24 Our diagnostics focus Patients suffering from gastrointestinal disease Mental Cardiovascular Cancer Autoimmune Allergy → Gastrointestinal Focusing, and solving this first will then enable us to advance to the next problem Why Gastrointestinal Disease? Millions of patients affected. Half are not getting a resolution 25 37,310,000 Patients presenting annually in the US with lower GI abdominal symptoms* 21,500,000 Pain, bloating, other 15,370,000 53% Resolved 47% Unresolved Diarrhoea 440,000 IBD % of patients achieving resolution of gastrointestinal symptoms after 5 years** * Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis completed with Boston based MedTech specialist consultancy Veranex Inc. ** Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623 *** 26 SUB-SECTION 2.2 The Diagnostic Solution Microba’s current comprehensive diagnostic products lead the market in addressing this problem head-on First line Diagnosing pathogenic causes of GI symptoms Gastrointestinal pathogen test Launched March 2024 – Currently sold to Medical Clinicians  Stool DNA test.  175 targets.  Expertly curated clinical recommendations for targeted treatment. Second line Identifying functional causes and treatment options for non-pathogenic GI symptoms Gastrointestinal disorder test Launched February 2023 – Currently sold to IFM Clinicians  Stool DNA + targeted biomarker test.  7 functional GI markers. >28k microbiome markers.  Expertly curated clinical recommendations for personalised treatment. 27 Getting answers for patients in need 28 Microba’s diagnostic products are closing the gap on GI symptom diagnosis and treatment 100% 47% * 50% ** 0% * Study of first 17 months of MetaXplore test results in clinical practice in Australia ** Study of first 4 months of MetaPanel test results in clinical practice in Australia ** 24% new diagnoses with Unresolved % of patients achieving resolution of gastrointestinal symptoms after 5 years 28% new insights with 52% receiving critical new diagnoses and treatment recommendation for these patients. 29 SUB-SECTION 3.2 Diagnostic Market Opportunity A multi-billion dollar market opportunity $25B+ Total Market Size* * Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims analysis for target patient populations, extrapolated Private and Medicaid numbers, populations and prevalence adjusted for key global markets spanning outside of US including Germany, Italy, Spain, France, United Kingdom and Australia. Pricing predicates based on approved CPT coding, reimbursed predicates, and other regional conservative pricing predicates. 30 31 SUB-SECTION 3.3 Customer flow and revenue model Customer flow and revenue model Practitioner referral • • Patient presents to Practitioner with GI symptoms Practitioner provides referral for a test Patient orders test & receives sampling kit • • • Patient fulfills referral test online using referral Patient pays test price Sampling kit sent express, or collected from partner pathology collection point 32 Patient takes sample & returns to Microba • • Patient completes sample collection at home Returns sample to Microba in supplied reply-paid express envelope, or drops off at partner pathology collection point – received within 24-48 hrs Lab processes test & delivers report • • • • • Sample received by central lab and processed QA, expert & pathologist review complete & signed off Report delivered to referring clinician 7-14 days from sample receipt to report delivery Once report is delivered to the HCP – test recognised as revenue 33 SUB-SECTION 3.4 Product Deep Dive At Microba, Product combines all disciplines of the business to deliver value to market. Test Ops Science Making sure we can quickly and reliably perform tests and deliver results Making our test results accurate, clinically useful, and scientifically supported Exception Handling Code that handles unexpected situations gracefully Telemetry Tech Code/Hardware that performs some function Tech Code/Hardware that performs some function c Real-time signals that inform product improvements Product Everything working together Strategy Most people think product is this A roadmap of ongoing improvements Growth Sales activities that convert interest into paying users that stay long-term Self-serve Easy for users to adopt and to get help Product Marketing Understand market needs. Articulate product value. Microba has two kinds of products 35 Our Apps host and distribute our range of precision Tests the same way YouTube apps host and distribute Videos. Apps Tests Patient App MetaXplore Clinician App PMS/EMR Integrations Internal Tools + MetaPanel [Next generation tests] ... User Experience Multi-channel Ordering Clinician Web Portal PMS/EMR Continuous Patient & Clinician Communication 36 Easy-to-read Interactive Reports Easy Sharing with Care Network Product Principles Driven by Purpose We prioritise patient engagement, understanding and health outcomes above all else. We work to balance the needs of a clinician's busy schedule and their need to apply their own clinical judgment. Therefore, we provide both easy to interpret high-level summaries and detailed deep-dive data. Scientifically Rigorous Reports are always grounded in science and evidence. We carefully and intentionally choose our words to communicate precise meaning and evidence levels, but we do not avoid having opinions or being clear in our meaning. Brilliantly designed We use simple language that makes our reports easy to understand by both patients and clinicians. We use deeply intentional and beautiful design that sets a global standard for diagnostics. Crafted with care We build one adaptable software suite for all tests, markets, and channels. Universal capabilities that are sensitive to different markets. We craft a clear and compelling vision, while delivering in disciplined thin iterations. 37 Short-Term Product Strategy Business Objective Primary Opportunity Primary Initiative 38 Grow Testing Globally – 1 million Tests More useful More usable More accessible More visibility Supercharge Clinical Utility Incredible Easy-to-use Kit Experience All tests purchasable in all channels Increase Availability of Internal BI Project Lightspeed Project Origami Project Serenity Project Beacon Lightspeed high-level roadmap 39 Supercharging clinical utility one facet at a time Phase 1 Readability Phase 2 Coverage Continuous Background Improvement Analytical Performance Scientific Validity Turnaround Time Phase 3 Personalisation Phase 4 Actionability Phase 5 Patient Engagement Phase 6 Adherence Tracking Product Vision – A unified stack for all tests, markets & geos Unified Branding and Localisation Unified Stand Alone & In-line Self-serve Education & Support Unified Distribution Integrations Unified Apps Suite Unified Tests Suite Unified Testing Kit Unified CRM & Test Operations Tools Unified Bioinformatics Platform Unified Testing Rails Unified Infra 41 SUB-SECTION 3.5 Growth Deep Dive GTM – Customer Roadmap Phase 1 – Clinicians (B2B2C) Current Focus Phase 2 – Small Clinics (B2B2C) Phase 3 – Patient Activation (B2C2B) 42 Phase 4 – Hospitals & Healthcare networks (Enterprise) Phase 5 – Patient Initiated with on-demand clinician (B2C2B) GTM - Regions Roadmap Phase 1 – Australia Phase 2 – United Kingdom Current Focus Phase 3 – United States 43 Phase 4 – Italy Phase 5 – Spain Growth Strategy 44 Our go-to-market model employs multiple tactics Marketing 1st line & nurturing Engagement Direct Sales Face-to-face Education & Influencing Partners Extended Reach/Access, Credibility Events Access, Engagement, Credibility KOL Engagement & Advocacy Credibility & Amplification Evidence of Clinical Utility Relevance, Credibility Growth Stack - Channels & Tactics Our channels and tactics will grow aligned to the customer types we are targeting in a phased manner. We are currently focused on Phase 1 - Clinicians (B2B). Phase 1 - Current 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. Website Direct Sales Outreach Educational Workshops and Webinars Leveraging Key Opinion Leaders (KOLs) Peer-Reviewed Research and Publications Content Marketing & Ecosystem Digital Marketing and Advertising Lightweight Clinical Case-Studies Peer-to-peer Mentoring Clinician Community Forum Email marketing 45 Phase 3 - Later Phase 2 - Next 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. Website Direct Sales Outreach Educational Workshops and Webinars Leveraging Key Opinion Leaders (KOLs) Peer-Reviewed Research and Publications Content Marketing & Ecosystem Digital Marketing and Advertising Clinical Studies Peer-to-peer Mentoring Clinician Community Forum Email marketing 12. Creating Patient Demand to Influence Healthcare Professional 13. Product-Led Growth 14. Building a Community 15. Affiliate or Referral Programs 16. Attending and Sponsoring Conferences 17. Brand Storytelling and Thought Leadership 18. Social Media 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. Website Direct Sales Outreach Educational Workshops and Webinars Leveraging Key Opinion Leaders (KOLs) Peer-Reviewed Research and Publications Content Marketing & Ecosystem Digital Marketing and Advertising Clinical Studies Peer-to-peer Mentoring Clinician Community Forum Email marketing 12. Creating Patient Demand to Influence Healthcare Professional 13. Product-Led Growth 14. Building a Community 15. Affiliate or Referral Programs 16. Attending and Sponsoring Conferences 17. Brand Storytelling and Thought Leadership 18. Social Media 19. Integration with Electronic Health Records (EHRs) 20. Offering Continuing Education Credits 21. Reimbursement Examples of Marketing & Sales Tools 46 MetaPanel: One Test, 175 Answers - Detecting difficult-to-diagnose pathogens MetaPanel Doctors Brochure Pathogen Target List Sample Report MetaPanel Patient Brochure CC RWE White Paper Real-World Case Scenarios Examples of Marketing & Sales Tools MetaXplore – enabling better informed clinical decisions for chronic GI disorders Sales Deck Sample Report Demo Clinician Brochures Product Fact Sheets Report Interpretation Support Tools Patient Handouts Clinical Webinars Microlearning Videos Science Review Whitepaper Clinical Scenario Use Cases 47 Direct Sales Outreach – Deep Dive Proactive medical best practice sales with partner leverage Highly trained sales reps Channel Specific Expertise (IFM & Medical) Structured Sales Incentives Sales Commission + SPIFs An effective sales philosoph